Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Beta radiation emitter
DRUG CLASS:
Beta radiation emitter
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
lutetium Lu 177 vipivotide tetraxetan (4)
lutetium Lu 177 dotatate (2)
177Lu-HER3 ARC (0)
AAA603 (0)
CAM-H2 (0)
ITM-31 (0)
yttrium-90 microspheres (0)
177Lu-edotreotide (0)
yttrium 90 microspheres (0)
177 Lu-FC705 (0)
lutetium Lu 177 vipivotide tetraxetan (4)
lutetium Lu 177 dotatate (2)
177Lu-HER3 ARC (0)
AAA603 (0)
CAM-H2 (0)
ITM-31 (0)
yttrium-90 microspheres (0)
177Lu-edotreotide (0)
yttrium 90 microspheres (0)
177 Lu-FC705 (0)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
FOLH1 positive
Prostate Cancer
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
lutetium Lu 177 vipivotide tetraxetan
Sensitive: B - Late Trials
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
B
FOLH1 expression
Prostate Cancer
FOLH1 expression
Prostate Cancer
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C3 – Early Trials
pembrolizumab + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C3
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
enzalutamide + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
enzalutamide + lutetium Lu 177 vipivotide tetraxetan
Sensitive: C4 – Case Studies
enzalutamide + lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
C4
SSTR2 underexpression
Neuroendocrine Tumor
SSTR2 underexpression
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login